| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| E C Tan, S A Chong, R Mahendran, F Dong, C H Ta. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biological psychiatry. vol 50. issue 2. 2001-12-10. PMID:11526996. |
case-control association studies have identified the t102c polymorphism of the 5-ht2a receptor gene as being associated with schizophrenia and responsiveness to clozapine. |
2001-12-10 |
2023-08-12 |
Not clear |
| I Murad, I Kremer, M Dobrusin, M Muhaheed, I Bannoura, D J Müller, T G Schulze, A Reshef, M Blanaru, S Gathas, V Tsenter, M Rietschel, R H Belmaker, W Maier, R P Ebstei. A family-based study of the Cys23Ser 5HT2C serotonin receptor polymorphism in schizophrenia. American journal of medical genetics. vol 105. issue 3. 2001-12-04. PMID:11353441. |
the 5ht2c receptor has a high affinity for clozapine, a nontypical neuroleptic, and has therefore been postulated to play a role in mediating negative symptoms and neuroleptic response in schizophrenia. |
2001-12-04 |
2023-08-12 |
Not clear |
| E F Cheun. Obsessive-compulsive symptoms during treatment with clozapine in a patient with schizophrenia. The Australian and New Zealand journal of psychiatry. vol 35. issue 5. 2001-12-04. PMID:11551293. |
obsessive-compulsive symptoms during treatment with clozapine in a patient with schizophrenia. |
2001-12-04 |
2023-08-12 |
Not clear |
| J R Bustillo, J Lauriello, L M Rowland, R E Jung, H Petropoulos, B L Hart, J Blanchard, S J Keith, W M Brook. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. Psychiatry research. vol 107. issue 3. 2001-12-04. PMID:11566430. |
effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. |
2001-12-04 |
2023-08-12 |
Not clear |
| I Gaertner, H J Gaertner, R Vonthein, K Diet. Therapeutic drug monitoring of clozapine in relapse prevention: a five-year prospective study. Journal of clinical psychopharmacology. vol 21. issue 3. 2001-11-01. PMID:11386494. |
twenty-three outpatients with schizophrenia (icd-10 f20.xx) treated with clozapine (cz) as monotherapy entered a prospective study on relapse prevention. |
2001-11-01 |
2023-08-12 |
Not clear |
| F E Scheepers, C C Gispen-de Wied, H G Westenberg, R S Kah. The effect of olanzapine treatment on monoamine metabolite concentrations in the cerebrospinal fluid of schizophrenic patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 25. issue 4. 2001-11-01. PMID:11557160. |
the mechanism of action of both typical antipsychotics and the atypical antipsychotic, clozapine, may be related to the (changing) interaction of dopamine and serotonin in schizophrenia. |
2001-11-01 |
2023-08-12 |
Not clear |
| J M Kane, S R Marder, N R Schooler, W C Wirshing, D Umbricht, R W Baker, D A Wirshing, A Safferman, R Ganguli, M McMeniman, M Borenstei. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Archives of general psychiatry. vol 58. issue 10. 2001-11-01. PMID:11576036. |
clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. |
2001-11-01 |
2023-08-12 |
Not clear |
| D C Henderso. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. The Journal of clinical psychiatry. vol 62 Suppl 23. 2001-11-01. PMID:11603884. |
clozapine remains the most effective agent for treatment-resistant patients with schizophrenia. |
2001-11-01 |
2023-08-12 |
Not clear |
| D C Henderso. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. The Journal of clinical psychiatry. vol 62 Suppl 23. 2001-11-01. PMID:11603884. |
despite the potential risks of medical morbidities, clozapine continues to have a major role in the care of treatment-resistant patients with schizophrenia. |
2001-11-01 |
2023-08-12 |
Not clear |
| V S Basile, M Masellis, R S McIntyre, H Y Meltzer, J A Lieberman, J L Kenned. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. The Journal of clinical psychiatry. vol 62 Suppl 23. 2001-11-01. PMID:11603885. |
prospective weight gain data were obtained for 80 patients with schizophrenia who completed a structured clozapine trial. |
2001-11-01 |
2023-08-12 |
Not clear |
| O Ohmori, T Shinkai, H Hori, J Nakamur. Novel polymorphism in the 5'-upstream region of the human 5-HT6 receptor gene and schizophrenia. Neuroscience letters. vol 310. issue 1. 2001-10-25. PMID:11524147. |
the localization of 5-hydroxytryptamine6 (5-ht6) receptor in the limbic and cortical regions, and the high affinity of atypical antipsychotic drugs such as clozapine for the receptor, suggest the possible involvement of the receptor in the pathogenesis of schizophrenia. |
2001-10-25 |
2023-08-12 |
human |
| G Orr, H Munitz, H Hermes. Low-dose clozapine for the treatment of Parkinson's disease in a patient with schizophrenia. Clinical neuropharmacology. vol 24. issue 2. 2001-10-18. PMID:11307050. |
low-dose clozapine for the treatment of parkinson's disease in a patient with schizophrenia. |
2001-10-18 |
2023-08-12 |
Not clear |
| G Orr, H Munitz, H Hermes. Low-dose clozapine for the treatment of Parkinson's disease in a patient with schizophrenia. Clinical neuropharmacology. vol 24. issue 2. 2001-10-18. PMID:11307050. |
this report suggests that some patients with concomitant schizophrenia and pd-a difficult treatment challenge-may benefit from clozapine treatment alone for both disorders. |
2001-10-18 |
2023-08-12 |
Not clear |
| H Cohen, U Loewenthal, M A Matar, M Kotle. Reversal of pathologic cardiac parameters after transition from clozapine to olanzapine treatment: a case report. Clinical neuropharmacology. vol 24. issue 2. 2001-10-18. PMID:11307047. |
we present a case of a patient with long-standing schizophrenia who was treated with clozapine. |
2001-10-18 |
2023-08-12 |
Not clear |
| J Cramer, R Rosenheck, W Xu, W Henderson, J Thomas, D Charne. Detecting improvement in quality of life and symptomatology in schizophrenia. Schizophrenia bulletin. vol 27. issue 2. 2001-10-11. PMID:11354590. |
the veterans affairs (va) cooperative study of clozapine in refractory schizophrenia evaluated 423 patients on clozapine or haloperidol. |
2001-10-11 |
2023-08-12 |
Not clear |
| B K Lipska, Z Z Khaing, C S Weickert, D R Weinberge. BDNF mRNA expression in rat hippocampus and prefrontal cortex: effects of neonatal ventral hippocampal damage and antipsychotic drugs. The European journal of neuroscience. vol 14. issue 1. 2001-09-27. PMID:11488957. |
to clarify the effects of antipsychotic drugs used in the therapy of schizophrenia on bdnf mrna, we studied its expression in rats treated with clozapine and haloperidol and in rats with neonatal lesions of the ventral hippocampus, used as an animal model of schizophrenia. |
2001-09-27 |
2023-08-12 |
rat |
| D C Henderson, D C Goff, C E Connolly, C P Borba, D Hayde. Risperidone added to clozapine: impact on serum prolactin levels. The Journal of clinical psychiatry. vol 62. issue 8. 2001-09-27. PMID:11561931. |
several years ago, we reported that the addition of risperidone to clozapine improved response in some patients with schizophrenia. |
2001-09-27 |
2023-08-12 |
Not clear |
| D C Henderson, D C Goff, C E Connolly, C P Borba, D Hayde. Risperidone added to clozapine: impact on serum prolactin levels. The Journal of clinical psychiatry. vol 62. issue 8. 2001-09-27. PMID:11561931. |
the goal of this study was to determine whether the addition of risperidone to clozapine results in an elevation of serum prolactin levels in patients with chronic schizophrenia or schizoaffective disorder. |
2001-09-27 |
2023-08-12 |
Not clear |
| S J Tsai, Y H Huang, H J Huang, C B Si. Reduced regional [14C]2-deoxyglucose uptake in response to long-term clozapine administration in rats. Neuropsychobiology. vol 44. issue 1. 2001-08-30. PMID:11408791. |
clozapine has superior effects in treating negative symptoms of schizophrenia and causes less extrapyramidal side effects than traditional antipsychotics. |
2001-08-30 |
2023-08-12 |
rat |
| L Tamam, N Ozpoyra. Suicide during clozapine treatment: a case report. The Israel journal of psychiatry and related sciences. vol 38. issue 2. 2001-08-30. PMID:11475915. |
although clozapine, along with its other significant features, has been reported to decrease suicidality and suicide rate among schizophrenia patients, physicians should remain vigilant for general risk factors of suicide in patients with schizophrenia during a treatment course and assess them carefully. |
2001-08-30 |
2023-08-12 |
Not clear |